LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

ABO Blood Group Related to Specific Immune Response to Anti-SARS-CoV-2

By LabMedica International staff writers
Posted on 31 Jan 2022
Print article
Image: The MACSQuant Analyzer 16 is engineered to expand the horizons of automated data acquisition with 16 optical parameters (Photo courtesy of Miltenyi Biotec)
Image: The MACSQuant Analyzer 16 is engineered to expand the horizons of automated data acquisition with 16 optical parameters (Photo courtesy of Miltenyi Biotec)
Markers of the protective humoral response, such as total anti-SARS-CoV-2 immunoglobulins and neutralizing antibodies, have been observed to decrease in convalescent individuals, even though a potential long-lasting humoral B-cell memory subset was detected.

The detection of these specific T-cells comprises evidence for potential preexisting immunity mediated by T-cells cross-reactive to human common-cold coronaviruses, which might protect against SARS-CoV-2 infection. Induced T-cell immunity also appears to play a critical role in SARS-CoV-2 clearance, with studies reporting strong T-cell responses in acute infection up to the convalescence phase.

Immunologists at the Gregorio Marañón University General Hospital (Madrid Spain) collected blood samples 12 to 305 days after positive polymerase chain reactions (PCRs) from 35 recovered individuals infected by SARS-CoV-2. Peripheral blood mononuclear cells were stimulated with SARS-CoV-2-derived peptide pools, such as the spike (S), nucleocapsid (N) and membrane (M) proteins, and the team quantified anti-S immunoglobulins in plasma.

Whole blood was labeled for surface markers to determine the absolute numbers of lymphocytes or CD4+ and CD8+ T cells. Absolute numbers of cellular subsets were determined using Flow-Count Fluorospheres (Beckman Coulter, Nyon, Switzerland). Flow cytometry analyzed surface markers using a MACSQuant Analyzer 16 cytometer (Miltenyi Biotec, Bergisch Gladbach, Germany). Peptide-specific T-cells were characterized after six hours of stimulation by cell surface and intracellular cytokine staining and the cells were then analyzed by flow cytometry, using a Beckman Coulter Gallios cytometer. To detect the presence or absence of A, B, and/or RhD antigens on red blood cells, DiaClon Anti-A, DiaClon Anti-B, DiaClon Anti-AB, and DiaClon Anti-D (Bio-Rad, Basel, Switzerland) were used.

The investigators reported that after 10 months post-infection, they observed a sustained SARS-CoV-2-specific CD4+ T-cell response directed against M-protein, but responses against S- or N-proteins were lost over time. They also demonstrated that O-group individuals presented significantly lower frequencies of specific CD4+ T-cell responses against membrane glycoprotein (Pep-M) than non O-group individuals. The non O-group subjects also needed longer to clear the virus, and they lost cellular immune responses over time, compared to the O-group individuals, who showed a persistent specific immune response against SARS-CoV-2.

The authors concluded that their results confirmed the existence of SARS-CoV-2-specific CD4+ T-cell and humoral responses in the majority of the individuals who had recovered from COVID-19 at 10 months post-infection. However, the response generated by the virus was identified as a predominantly CD4+ T-cell over CD8+ T-cell response, with more robust responses against M- or S-peptide pools over nucleocapsid phosphoprotein (Pep-N). A more in-depth analysis demonstrated that the intensity of the humoral and memory T-cell response might be related to the ABO blood group and age. The study was published in the January 2022 issue of the journal Virulence.

Related Links:
Gregorio Marañón University General Hospital
Beckman Coulter
Miltenyi Biotec
Bio-Rad


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.